# Does resistance training exercise help prevent frailty and loss of independence for older people with insulin treated diabetes? The EXPLODE Trial

| Submission date   | Recruitment status  No longer recruiting          | [X] Prospectively registered                  |  |  |
|-------------------|---|---|--|--|
| 15/07/2020        |   | [X] Protocol                                  |  |  |
| Registration date | Overall study status Completed Condition category | Statistical analysis plan                     |  |  |
| 03/08/2020        |   | Results                                       |  |  |
| Last Edited       |   | Individual participant data                   |  |  |
| 16/01/2023        | Nutritional, Metabolic, Endocrine                 | <ul><li>Record updated in last year</li></ul> |  |  |

## Plain English summary of protocol

Background and study aims

There are 3.7 million people in the UK with diagnosed diabetes (both Type 1 and Type 2), with approximately 80% treated with insulin or requiring insulin treatment at some stage of the disease. While diabetes complications such as cardiovascular disease are well known, often unappreciated complications are the accelerated rate of sarcopenia (loss of bone mass), increased frailty, and loss of independence that can come from years of exposure to hyperglycaemia and inflammation.

Leading a physically active life can be problematic for those with insulin-treated diabetes due to blood glucose control disruption. However, resistance (weight) training carries less risk of a loss of blood glucose control, compared to other forms of exercise. Moreover, in other groups of people with frailty, resistance training has been shown effective in improving physical function. With the increasing prevalence of diabetes, planning for the management of this patient group in later life is vital.

The aim of this study is to test the use of resistance exercise to improve physical function in older patients with insulin treated diabetes, who are mildly frail. This study also aims to increase understanding of the impact of resistance training on patients with diabetes psycho-socially. Findings will be used to inform a future trial should the training prove acceptable and feasible.

## Who can participate?

Thirty patients with insulin-treated diabetes (type 1 and 2), and thirty without (matched for age and frailty), aged 60 or over, will be recruited.

#### What does the study involve?

All participants will complete blood and physical testing. Fifteen of each group will then be randomised to a four-week supervised resistance training programme, designed to increase muscle mass/strength. All participants will then repeat the physical testing. A subset will be

interviewed before and after the training programme to understand their perceptions of training, and living with diabetes (where relevant) as they have aged.

What are the possible benefits and risks of participating? There is no direct benefit for participants. However, exercise is repeatedly shown to be of benefit, both physically and mentally.

All participants will be screened before taking part in the study, to ensure that they do not have any conditions which exercise may exacerbate. This is to ensure safety.

The resistance training programme is designed to be accessible to all, building gradually over the four week period. Participants will be fully supervised, and weights will be adjusted to what they can easily lift (rather than a specific kilogram weight).

Blood samples will be taken as part of the study, there is the risk of slight discomfort or bruising. These risks will be minimised by samples being taken by experienced clinical staff.

The study requires frequent visits to the CRF which may cause a time inconvenience for participants. Participants will be reimbursed £50 for taking part in the study as compensation for their time. Transportation will be provided for all visits. Participants' visits will also be scheduled at the convenience of the participant, such that any inconvenience is minimised.

Where is the study run from? Newcastle University (UK) and the Clinical Research Facility at the Royal Victoria Infirmary, Newcastle-upon-Tyne (UK)

When is the study starting and how long is it expected to run for? From December 2019 to April 2025

Who is funding the study? Internal Newcastle University funding supported by the Wellcome Trust small grant scheme (UK)

Who is the main contact?
Dr Daniel West
daniel.west@newcastle.ac.uk

## **Contact information**

## Type(s)

Scientific

#### Contact name

Dr Daniel West

#### Contact details

Institute of Cellular Medicine Room M4.077, William Leech Building Newcastle-upon-Tyne United Kingdom NE2 4HH +44 (0)1912087076 daniel.west@newcastle.ac.uk

## Type(s)

Public

#### Contact name

Dr Daniel West

#### Contact details

Institute of Cellular Medicine Room M4.077, William Leech Building Newcastle-upon-Tyne United Kingdom NE2 4HH +44 (0)1912087076 daniel.west@newcastle.ac.uk

## Type(s)

**Public** 

#### Contact name

Dr Rachel Stocker

#### Contact details

Institute of Cellular Medicine Room M4.077, William Leech Building Newcastle-upon-Tyne United Kingdom NE2 4HH +44 (0)1912082057 rachel.stocker@newcastle.ac.uk

## Additional identifiers

## **EudraCT/CTIS** number

Nil known

#### **IRAS** number

269661

## ClinicalTrials.gov number

Nil known

## Secondary identifying numbers

IRAS 269661

# Study information

#### Scientific Title

EXercise to Prevent frailty and Loss Of independence in insulin treated older people with DiabetEs: The EXPLODE Trial

#### Acronym

**EXPLODE** 

## **Study objectives**

The aim of this trial is to characterise the physical function, cardiovascular health, and the health and wellbeing of older people living with diabetes, and compare that to a matched control group.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Pending review on 15/07/2020, NHS North East - Newcastle & North Tyneside 2 Research Ethics Committee (NHS BT Blood Donor Centre, Holland Drive, HRA Newcastle, UK, NE2 4NQ; newcastlenorthtyneside2.rec@hra.nhs.uk; +44 (0)207 104 8222). ref: 20/NE/0178

#### Study design

Single-centre interventional parallel group feasibility randomised controlled trial

#### Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Community

## Study type(s)

Quality of life

#### Participant information sheet

Not available in web format, please use contact details to request a participant information sheet.

#### Health condition(s) or problem(s) studied

Type 1 diabetes and type 2 diabetes treated with exogenous insulin

#### **Interventions**

All participants will complete baseline blood and physical testing. Participants will then be randomised (1:1 ratio) to either:

- 1. Intervention group, a 4-week programme of supervised resistance exercise training
- 2. Control group, where participants will be instructed to carry on with any usual activity as normal

Randomisation will be carried out online by a member of the study team, using https://www.sealedenvelope.com

All participants will then repeat the physical testing. A subset will also be interviewed before and after the training programme to understand their perceptions of training, and living with diabetes (where relevant) as they have aged.

## Intervention Type

Behavioural

## Primary outcome measure

Feasibility of carrying out a larger trial, measured using recruitment and retention rate, and the acceptability of intervention of resistance exercise as assessed using an interview of a subset of participants at baseline and 5 weeks

## Secondary outcome measures

- 1. Body composition measured using height, weight, waist circumference, percentage body fat, and percentage fat-free mass using bioelectrical impedance analysis at baseline and 5 weeks
- 2. Isometric strength measured using a torque and strain gauge at baseline and 5 weeks
- 3. Handgrip strength measured using a digital handgrip dynamometer at baseline and 5 weeks
- 4. Gait speed measured using three 4 m walking tests on digital timing gates at baseline and 5 weeks
- 5. Timed sit to stand, measured using five sit to stand movements at baseline and 5 weeks
- 6. Cardiovascular health measured using resting blood pressure, HbA1c, blood lipid profile, and inflammatory cytokines at baseline and 5 weeks
- 7. Wellbeing, activity levels, and (where applicable) views on the resistance training programme and diabetes management, measured narratively using a nested qualitative interview study at baseline and 5 weeks

## Overall study start date

01/12/2019

## Completion date

01/04/2025

# **Eligibility**

## Key inclusion criteria

- 1. Aged ≥60 years
- 2. Rockwood Clinical Frailty Score of 3 or 4
- 3. Diagnosis of type 1 or type 2 diabetes mellitus, or age and frailty matched non-diabetic control

## Participant type(s)

Mixed

## Age group

Adult

#### Lower age limit

60 Years

#### Sex

#### Both

## Target number of participants

60

## Key exclusion criteria

- 1. Myocardial infarction in the last 12 months
- 2. Stroke in the last 12 months
- 3. Renal failure in the last 12 months
- 4. Liver disease in the last 12 months
- 5. Inability to give consent

#### Date of first enrolment

01/10/2020

## Date of final enrolment

31/01/2025

## Locations

#### Countries of recruitment

England

**United Kingdom** 

## Study participating centre

Newcastle upon Tyne Hospitals NHS Foundation Trust

Leazes Wing Main Entrance Royal Victoria Infirmary Queen Victoria Road Newcastle upon Tyne United Kingdom NE1 4LP

# **Sponsor information**

## Organisation

Newcastle upon Tyne Hospitals NHS Foundation Trust

## Sponsor details

Level 1, Regent Point Regent Farm Road Gosforth Newcastle-upon-Tyne England United Kingdom NE3 3HD +44 (0)1912824520 nuth.nuthsponsorship@nhs.net

## Sponsor type

Hospital/treatment centre

## Website

http://www.newcastle-hospitals.org.uk/

#### **ROR**

https://ror.org/05p40t847

# Funder(s)

## Funder type

University/education

#### **Funder Name**

Faculty of Medical Sciences, Newcastle University

## Alternative Name(s)

**FMS** 

## Funding Body Type

Private sector organisation

## **Funding Body Subtype**

Universities (academic only)

#### Location

United Kingdom

#### **Funder Name**

Wellcome Trust

## Alternative Name(s)

## **Funding Body Type**

Private sector organisation

## **Funding Body Subtype**

International organizations

## Location

**United Kingdom** 

# **Results and Publications**

## Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal and at scientific conferences

## Intention to publish date

30/09/2026

## Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date

## IPD sharing plan summary

Not provided at time of registration

## **Study outputs**

| Output type             | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|-------------------------|---------|--------------|------------|----------------|-----------------|
| <u>Protocol article</u> |         | 08/12/2021   | 10/12/2021 | Yes            | No              |
| HRA research summary    |         |              | 28/06/2023 | No             | No              |